| Pharmaceutical Information |
| Drug Name |
Hyaluronidase (human recombinant) |
| Drug ID |
BADD_D01079 |
| Description |
A purified preparation of the enzyme recombinant human hyaluronidase. Hyaluronidase (human recombinant) (INN Vorhyaluronidase alfa) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20).[A4033] Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.[L13338] The action of hyaluronidase was first described in 1936, and named in 1939.[A199026] Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue.[A199026] Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.[A199047]
Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338] |
| Indications and Usage |
Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography.[L13338] Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.[L13338] |
| Marketing Status |
approved; investigational |
| ATC Code |
B06AA03 |
| DrugBank ID |
DB06205
|
| KEGG ID |
D04455; D06604; D04456
|
| MeSH ID |
D006821
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
50090-4534; 18657-117 |
| UNII |
743QUY4VD8
|
| Synonyms |
Hyaluronoglucosaminidase | Hyaluronidase | Hyaglosidase | Hyaluronate Hydrolase | Hydrolase, Hyaluronate | Duran-Reynals Permeability Factor | Duran Reynals Permeability Factor | Factor, Duran-Reynals Permeability | Permeability Factor, Duran-Reynals | GL Enzyme | Wydase |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
757971-58-7 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
